Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey P Nadler

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Current Infectious Disease Reports|April 26, 2005
New HIV Drugs in Development, 2005Jeffrey P Nadler, Michael C Phillips
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 2, 2002
Daily dosing of highly active antiretroviral therapyKeith A Rosenbach, Robert Allison, Jeffrey P Nadler
Journal of Acquired Immune Deficiency Syndromes (1999)|May 21, 2005
Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in Western IndiaSanjay N Pujari, Ameet Dravid, Eknath Naik, et al.
The AIDS Reader|July 13, 2004
Anemia prevalence and associated risk factors in a single-center ambulatory HIV clinical cohortTodd S Wills, Jeffrey P Nadler, Charurut Somboonwit, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 7, 2004
The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patientsAmalia Rodriguez-French, Jack Boghossian, Glenda E Gray, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 11, 2002
Open-label study of a twice-daily indinavir 800-mg/ritonavir 200-mg regimen in HIV-infected adults failing a protease inhibitor regimenHarold P Katner, David P Paar, Jeffrey P Nadler, et al.
BMC Infectious Diseases|June 11, 2003
Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patientsJeffrey P Nadler, Joseph C Gathe, Richard B Pollard, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 20, 2002
Predicting death from HIV/AIDS: a case-control study from Florida public HIV/AIDS clinicsSpencer Lieb, Robert G Brooks, Richard S Hopkins, et al.
AIDS (London, England)|April 7, 2007
Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis, Jeffrey P Nadler, Daniel S Berger, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Current Infectious Disease Reports|April 26, 2005
New HIV Drugs in Development, 2005Jeffrey P Nadler, Michael C Phillips
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 2, 2002
Daily dosing of highly active antiretroviral therapyKeith A Rosenbach, Robert Allison, Jeffrey P Nadler
Journal of Acquired Immune Deficiency Syndromes (1999)|May 21, 2005
Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in Western IndiaSanjay N Pujari, Ameet Dravid, Eknath Naik, et al.
The AIDS Reader|July 13, 2004
Anemia prevalence and associated risk factors in a single-center ambulatory HIV clinical cohortTodd S Wills, Jeffrey P Nadler, Charurut Somboonwit, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 7, 2004
The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patientsAmalia Rodriguez-French, Jack Boghossian, Glenda E Gray, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 11, 2002
Open-label study of a twice-daily indinavir 800-mg/ritonavir 200-mg regimen in HIV-infected adults failing a protease inhibitor regimenHarold P Katner, David P Paar, Jeffrey P Nadler, et al.
BMC Infectious Diseases|June 11, 2003
Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patientsJeffrey P Nadler, Joseph C Gathe, Richard B Pollard, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 20, 2002
Predicting death from HIV/AIDS: a case-control study from Florida public HIV/AIDS clinicsSpencer Lieb, Robert G Brooks, Richard S Hopkins, et al.
AIDS (London, England)|April 7, 2007
Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis, Jeffrey P Nadler, Daniel S Berger, et al.
Pageof 1